Ocular Myasthenia Gravis Scores Improve With Subcutaneous Treatment

(MedPage Today) -- Subcutaneous efgartigimod PH20 (Vyvgart Hytrulo) met the primary endpoint in the phase III ADAPT OCULUS trial of people with ocular myasthenia gravis show, interim data showed. At 4 weeks, ocular myasthenia gravis patients treated...